Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MVD | P53602 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532438 | 0.74 | — | — | |
| SCHEMBL9911438 | 0.74 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA4SMN1; SMN2 | |
| SCHEMBL18811589 | 0.71 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA4SMN1; SMN2 | |
| SCHEMBL14759238 | 0.69 | ALDH1A1 (0.37) | CHRNB2CHRNB4CHRNA4SMN1; SMN2 | |
| SCHEMBL28234432 | 0.69 | TPI1 (0.46) | SMN1; SMN2MVD | |
| SCHEMBL13301622 | 0.69 | MVD (0.38) | SMN1; SMN2MVD | |
| SCHEMBL20175276 | 0.68 | SMN1; SMN2 (0.33) | SMN1; SMN2MVD | |
| SCHEMBL28033074 | 0.64 | KDM4E (0.39) | CHRNB2CHRNB4CHRNA4SMN1; SMN2 | |
| SCHEMBL1258611 | 0.64 | ALDH1A1 (0.42) | CHRNB2CHRNB4CHRNA4SMN1; SMN2 | |
| SCHEMBL27998922 | 0.63 | TSHR (0.50) | GABBR2GABBR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180142321-A1 | USE OF NOVEL COMPOUNDS FOR SELECTIVELY EXTRACTING RARE EARTHS FROM AQUEOUS SOLUTIONS INCLUDING PHOSPHORIC ACID AND ASSOCIATED EXTRACTION METHOD | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180142321-A1 | USE OF NOVEL COMPOUNDS FOR SELECTIVELY EXTRACTING RARE EARTHS FROM AQUEOUS SOLUTIONS INCLUDING PHOSPHORIC ACID AND ASSOCIATED EXTRACTION METHOD | HRH3, ALK, H1-0 | CHRNB2 4389/4885CHRNB4 4283/4885CHRNA4 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.